+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pulmonary Arterial Hypertension Market - Global Forecast 2026-2032- Product Image
Pulmonary Arterial Hypertension Market - Global Forecast 2026-2032- Product Image
New

Pulmonary Arterial Hypertension Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5011141
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pulmonary arterial hypertension market is experiencing significant changes as new therapies, evolving diagnostics, and shifting regulatory priorities redefine how organizations approach treatment, reimbursement, and competitive strategy. For senior executives, understanding these changes is essential for guiding portfolio choices, optimizing access, and supporting sustainable business growth.

Pulmonary Arterial Hypertension Market Snapshot

The pulmonary arterial hypertension market is showing steady expansion, growing from USD 9.77 billion in 2025 to USD 10.46 billion in 2026. With an anticipated CAGR of 7.73%, it is forecasted to reach USD 16.45 billion by 2032. This trajectory is propelled by ongoing advancements in clinical science, sophisticated care models, and regulatory developments across global healthcare systems. As innovative therapies and policy changes reshape reimbursement, procurement strategies, and access pathways, stakeholders are adjusting their approaches to remain aligned with evolving market conditions.

Scope & Segmentation

This report delivers a comprehensive analysis of pulmonary arterial hypertension market dynamics, with insight into trends shaping clinical decisions, regulatory frameworks, and commercial opportunities. Segmentation is structured around multiple dimensions to reflect market complexity:

  • Drug Class: Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostanoids, offering differentiated mechanisms and therapy options for patients and prescribers.
  • Route of Administration: Intravenous, oral, and subcutaneous formulations, each influencing treatment adherence, convenience, and clinical practice patterns.
  • Distribution Channel: Hospital pharmacy, online pharmacy, and retail pharmacy, enabling tailored strategies for product placement and patient access.
  • End User Setting: Academic and research institutions, clinics, and hospitals, each with unique protocols for adopting new therapies and managing patient populations.
  • Regional Markets: Americas, Europe, Middle East & Africa, and Asia-Pacific, where regulatory frameworks, payer priorities, and infrastructure maturity drive distinct opportunities and risks.
  • Technologies: Advanced biomarkers, imaging modalities, and digital health platforms that support early disease identification, patient monitoring, and engagement.

Key Takeaways for Decision-Makers

  • Integrated clinical and commercial strategies are driving new approaches to patient management, including increased adoption of combination therapies and more personalized treatment models.
  • Innovative use of real-world data and adaptive clinical trial designs is supporting accelerated validation and reimbursement processes, meeting evolving payer and provider expectations.
  • Digital health tools, such as remote monitoring and enhanced diagnostics, are enabling earlier identification of risk and improved ongoing management for patients.
  • Regional market differences necessitate flexible pricing and access models, as procurement processes, reimbursement systems, and healthcare capacity can vary widely between geographies.
  • Strengthening supply chain resilience is now an operational priority, as organizations diversify sourcing and manufacturing partnerships to mitigate risks associated with policy changes.

Tariff Impact: Strategic Considerations for the U.S. Market

Proposed tariff changes in the United States have the potential to impact supply chains by raising costs for imported pharmaceutical components and finished medicines. Manufacturers are evaluating strategies such as expanding domestic production, diversifying suppliers, and adjusting manufacturing contracts to minimize disruption. These actions can alter procurement decisions and value-based contracting approaches as market participants respond to evolving cost structures. Smaller biopharmaceutical innovators may encounter additional obstacles, making proactive risk assessment and payer engagement essential for market continuity.

Research Methodology & Data Sources

This analysis utilizes a mixed-methods approach, integrating peer-reviewed clinical studies, regulatory reports, and primary interviews with clinicians, payers, pharmacists, and advocacy stakeholders. Triangulation of data, segmented by clinical, administrative, and regional perspectives, informs the conclusions. Recognized limitations include fluctuations in data availability and changing regulatory landscapes.

Pulmonary Arterial Hypertension Market: Why This Report Matters

  • Equips organizations with actionable intelligence to inform R&D, portfolio management, and commercialization tailored for dynamic clinical and payer environments.
  • Provides clarity on evolving stakeholder priorities, supporting competitive segmentation and market strategy.
  • Offers targeted guidance to improve supply chain resilience, optimize patient support initiatives, and enhance outcomes in a complex landscape.

Conclusion

Success in the pulmonary arterial hypertension market depends on adaptive, evidence-driven strategies that integrate clinical insight with robust supply and patient support frameworks. Executives prioritizing agile, regionally aligned planning are better positioned to create sustained value and improve patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Pulmonary Arterial Hypertension Market, by Drug Class
8.1. Endothelin Receptor Antagonists
8.2. Phosphodiesterase-5 Inhibitors
8.3. Prostanoids
9. Pulmonary Arterial Hypertension Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Pulmonary Arterial Hypertension Market, by Distribution
10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy
11. Pulmonary Arterial Hypertension Market, by End User
11.1. Academic & Research Institutions
11.2. Clinics
11.3. Hospitals
12. Pulmonary Arterial Hypertension Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Pulmonary Arterial Hypertension Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Pulmonary Arterial Hypertension Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Pulmonary Arterial Hypertension Market
16. China Pulmonary Arterial Hypertension Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Alembic Pharmaceuticals Limited
17.6. AstraZeneca PLC
17.7. Aurobindo Pharma Limited
17.8. Bayer AG
17.9. Boehringer Ingelheim GmbH
17.10. Cipla Limited
17.11. CMP Pharma, Inc.
17.12. Dr. Reddy’s Laboratories Limited
17.13. Eli Lilly and Company
17.14. Gilead Sciences, Inc.
17.15. GlaxoSmithKline PLC
17.16. Gossamer Bio, Inc.
17.17. Gyre Therapeutics, Inc.
17.18. Hikma Pharmaceuticals PLC
17.19. Johnson & Johnson Services, Inc.
17.20. Lupin Limited
17.21. Merck KGaA
17.22. Novartis AG
17.23. Pfizer, Inc.
17.24. Sun Pharmaceutical Industries Limited
17.25. Teva Pharmaceutical Industries Ltd.
17.26. Torrent Pharmaceuticals Limited
17.27. United Therapeutics Corporation
List of Figures
FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 44. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 45. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 46. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 47. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 48. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 50. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 51. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 52. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 53. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 55. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 56. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 57. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 63. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 65. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 66. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 67. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 70. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 72. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 75. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 77. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 88. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 93. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 96. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 98. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 101. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 103. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 108. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 113. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 116. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 117. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 119. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 121. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
TABLE 124. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Pulmonary Arterial Hypertension market report include:
  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 16.45 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market Report and Forecast 2025-2034 - Product Image

Pulmonary Arterial Hypertension Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 188 Pages
  • Global
From
Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2025-2033 - Product Image

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
Pulmonary Arterial Hypertension - Pipeline Insight, 2025 - Product Image

Pulmonary Arterial Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Familial Primary Pulmonary Hypertension - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Familial Primary Pulmonary Hypertension - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Pulmonary Arterial Hypertension Drug Market

Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening form of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is a type of cardiovascular disease, and is treated with a variety of drugs. These drugs are used to reduce symptoms, improve exercise capacity, and slow the progression of the disease. Commonly used drugs include prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. The PAH drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAH, the development of new drugs, and the increasing awareness of the disease. The market is expected to continue to grow in the coming years, as new drugs are developed and approved. Some of the major companies in the PAH drug market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.